Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.

Amy S Clark Fangxin Hong Richard S Finn Angela M DeMichele Edith P Mitchell James A Zwiebel Fernanda I Arnaldez Robert C Gray Xin Victoria Wang Lisa Meier McShane Lawrence V Rubinstein David R Patton P Mickey Williams Stanley R Hamilton Mehmet Sitki Copur Samer S Kasbari Ravneet Thind Barbara A Conley Carlos L Arteaga Peter J O'Dwyer Lyndsay N Harris Helen X Chen Keith T Flaherty

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Palbociclib was not effective at treating nonbreast solid tumors with a CCND1, 2, or 3 amplification in this cohort. These data do not support further investigation of single-agent palbociclib in tumors with CCND1, 2, or 3 amplification.

Keyphrases

phase ii study
nucleic acid
metastatic breast cancer
open label
locally advanced
clinical trial
label free
study protocol
phase iii
electronic health record
phase ii
squamous cell carcinoma
randomized controlled trial
placebo controlled
radiation therapy
artificial intelligence
double blind
data analysis